Overall, however, plasma biomarkers are more limited in ruling in AD pathology in non-AD clinical syndromes and follow-up testing with either PET or CSF may be warranted; in these instances, the topographical information provided by tau-PET47,48 may be useful. The gene discussed is MAPT; the disease is Alzheimer disease.